tiprankstipranks
Blurbs

Analysts Offer Insights on Healthcare Companies: Moderna (MRNA), CASI Pharmaceuticals (CASI) and Inhibikase Therapeutics (IKT)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Moderna (MRNAResearch Report), CASI Pharmaceuticals (CASIResearch Report) and Inhibikase Therapeutics (IKTResearch Report) with bullish sentiments.

Moderna (MRNA)

Brookline Capital Markets analyst Leah R. Cann maintained a Buy rating on Moderna today and set a price target of $506.00. The company’s shares closed last Monday at $177.92.

According to TipRanks.com, Cann is a 3-star analyst with an average return of 3.3% and a 46.0% success rate. Cann covers the Healthcare sector, focusing on stocks such as Crispr Therapeutics AG, Syros Pharmaceuticals, and Intellia Therapeutics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Moderna with a $217.89 average price target.

See Insiders’ Hot Stocks on TipRanks >>

CASI Pharmaceuticals (CASI)

H.C. Wainwright analyst Swayampakula Ramakanth maintained a Buy rating on CASI Pharmaceuticals today and set a price target of $12.00. The company’s shares closed last Monday at $3.66, close to its 52-week low of $2.24.

According to TipRanks.com, Ramakanth has 0 stars on 0-5 stars ranking scale with an average return of -3.7% and a 36.8% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Janux Therapeutics Inc, Harpoon Therapeutics, and Alaunos Therapeutics.

Currently, the analyst consensus on CASI Pharmaceuticals is a Strong Buy with an average price target of $31.00.

Inhibikase Therapeutics (IKT)

In a report released today, Soumit Roy from JonesTrading reiterated a Buy rating on Inhibikase Therapeutics, with a price target of $6.00. The company’s shares closed last Monday at $0.79, close to its 52-week low of $0.60.

According to TipRanks.com, Roy is a 4-star analyst with an average return of 5.7% and a 34.8% success rate. Roy covers the Healthcare sector, focusing on stocks such as Deciphera Pharmaceuticals, Actinium Pharmaceuticals, and Adaptimmune Therapeutics.

Currently, the analyst consensus on Inhibikase Therapeutics is a Moderate Buy with an average price target of $6.00.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on MRNA:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles